{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:43:24Z","timestamp":1790739804413,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier","isbn-type":[{"value":"9780128154182","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.irn.2018.08.002","type":"book-chapter","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T13:25:04Z","timestamp":1536240304000},"page":"173-210","source":"Crossref","is-referenced-by-count":28,"title":["Molecular Imaging of the Serotonergic System in Parkinson's Disease"],"prefix":"10.1016","author":[{"given":"Gennaro","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.08.002_bb9000","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"Journal of the Neurological Sciences"},{"issue":"10\u221212","key":"10.1016\/bs.irn.2018.08.002_bb0010","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s007020050124","article-title":"[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease","volume":"105","author":"Asenbaum","year":"1998","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","article-title":"Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease","volume":"27","author":"Ballanger","year":"2012","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1523\/JNEUROSCI.2830-16.2016","article-title":"A high-resolution in vivo atlas of the human brain's serotonin system","volume":"37","author":"Beliveau","year":"2017","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2018.08.002_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.12.012","article-title":"Re-emergent tremor in Parkinson's disease","volume":"36","author":"Belvisi","year":"2017","journal-title":"Parkinsonism & Related Disorders"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0002-8223(95)00269-3","article-title":"Weight change and body composition in patients with Parkinson's disease","volume":"95","author":"Beyer","year":"1995","journal-title":"Journal of the American Dietetic Association"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neures.2013.10.002","article-title":"Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia","volume":"77","author":"Bezard","year":"2013","journal-title":"Neuroscience Research"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.002_bb0045","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/mds.22212","article-title":"Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB","volume":"23","author":"Boileau","year":"2008","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiology of Aging"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.002_bb0055","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1212\/WNL.42.8.1554","article-title":"Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18F-dopa PET study","volume":"42","author":"Brooks","year":"1992","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2018.08.002_bb0060","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/acn3.246","article-title":"Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease","volume":"2","author":"Buddhala","year":"2015","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biopsych.2006.05.005","article-title":"Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography","volume":"60","author":"Cannon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.002_bb0070","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.biopsych.2007.03.016","article-title":"Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder","volume":"62","author":"Cannon","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.irn.2018.08.002_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","article-title":"Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia","volume":"198","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"issue":"Pt. 7","key":"10.1016\/bs.irn.2018.08.002_bb0080","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"Suppl 1","key":"10.1016\/bs.irn.2018.08.002_bb0085","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","article-title":"Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease","volume":"25","author":"Carta","year":"2010","journal-title":"Movement Disorders"},{"issue":"S 1-2","key":"10.1016\/bs.irn.2018.08.002_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0022-510X(00)00411-1","article-title":"Fatigue and basal ganglia","volume":"179","author":"Chaudhuri","year":"2000","journal-title":"Journal of the Neurological Sciences"},{"issue":"36","key":"10.1016\/bs.irn.2018.08.002_bb0095","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","article-title":"Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans","volume":"108","author":"Cirrito","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.002_bb0100","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2967\/jnumed.107.041905","article-title":"Test-retest reproducibility of 18F-MPPF PET in healthy humans: A reliability study","volume":"48","author":"Costes","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"issue":"9916","key":"10.1016\/bs.irn.2018.08.002_bb0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0115","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1748-1716.2009.02015.x","article-title":"Orexins\/hypocretins and aminergic systems","volume":"198","author":"Eriksson","year":"2010","journal-title":"Acta Physiologica (Oxford, England)"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nature Reviews. Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0130","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: On movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0135","first-page":"682","article-title":"Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans","volume":"45","author":"Frankle","year":"2004","journal-title":"Journal of Nuclear Medicine"},{"issue":"22","key":"10.1016\/bs.irn.2018.08.002_bb0140","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","article-title":"Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease","volume":"327","author":"Freed","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archneur.1990.00530050021007","article-title":"Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year","volume":"47","author":"Freed","year":"1990","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0150","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.410400609","article-title":"Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging","volume":"40","author":"Frey","year":"1996","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainresbull.2010.12.006","article-title":"Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats","volume":"84","author":"Gil","year":"2011","journal-title":"Brain Research Bulletin"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","article-title":"Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study","volume":"64","author":"Goetz","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0165","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jnnp.2008.159772","article-title":"Towards an understanding of fatigue in Parkinson disease","volume":"80","author":"Hagell","year":"2009","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.002_bb0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","article-title":"Dyskinesias following neural transplantation in Parkinson's disease","volume":"5","author":"Hagell","year":"2002","journal-title":"Nature Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31887\/DCNS.2004.6.3\/ahartmann","article-title":"Postmortem studies in Parkinson's disease","volume":"6","author":"Hartmann","year":"2004","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.002_bb0180","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0185","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pnpbp.2004.11.015","article-title":"Distinct effects of sleep deprivation on binding to norepinephrine and serotonin transporters in rat brain","volume":"29","author":"Hipolide","year":"2005","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"Hornung","year":"2003","journal-title":"Journal of Chemical Neuroanatomy"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1471-4159.2004.02585.x","article-title":"DASB\u2014In vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer","volume":"90","author":"Hummerich","year":"2004","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03159935","article-title":"Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway","volume":"14","author":"Jellinger","year":"1991","journal-title":"Molecular and Chemical Neuropathology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2013.10.014","article-title":"Looking beyond 5-HT(3) receptors: A review of the wider role of serotonin in the pharmacology of nausea and vomiting","volume":"722","author":"Johnston","year":"2014","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0210","first-page":"166","article-title":"The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle","volume":"64","author":"Jouvet","year":"1972","journal-title":"Ergebnisse der Physiologie, Biologischen Chemie und experimentellen Pharmakologie"},{"issue":"Suppl 1","key":"10.1016\/bs.irn.2018.08.002_bb0215","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.parkreldis.2017.07.023","article-title":"Biomarkers for cognitive dysfunction in Parkinson's disease","volume":"46","author":"Kalia","year":"2018","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0220","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0225","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archneur.60.9.1223","article-title":"Positron emission tomography of striatal serotonin transporters in Parkinson disease","volume":"60","author":"Kerenyi","year":"2003","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0230","first-page":"39","article-title":"Biochemistry of Parkinson's disease: Is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?","volume":"91","author":"Kish","year":"2003","journal-title":"Advances in Neurology"},{"issue":"Pt. 1","key":"10.1016\/bs.irn.2018.08.002_bb0235","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2018.08.002_bb0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fneur.2014.00084","article-title":"Mechanisms of body weight fluctuations in Parkinson's disease","volume":"5","author":"Kistner","year":"2014","journal-title":"Frontiers in Neurology"},{"issue":"10 Suppl. 3","key":"10.1016\/bs.irn.2018.08.002_bb0245","article-title":"Levodopa therapy in Parkinson's disease","volume":"40","author":"Koller","year":"1990","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0250","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.22691","article-title":"Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease","volume":"71","author":"Kotagal","year":"2012","journal-title":"Annals of Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.002_bb0255","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1001\/archneurol.2012.764","article-title":"Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease","volume":"69","author":"Kotagal","year":"2012","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/ana.25236","article-title":"Serotonin, beta-amyloid, and cognition in Parkinson disease","author":"Kotagal","year":"2018","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2018.08.002_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Archives of Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2018.08.002_bb0270","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.0000000000001909","article-title":"Putaminal serotonergic innervation: Monitoring dyskinesia risk in Parkinson disease","volume":"85","author":"Lee","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.002_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040166","article-title":"The role of serotonin in sleep disordered breathing associated with Parkinson disease: A correlative [11C]DASB PET imaging study","volume":"7","author":"Lelieveld","year":"2012","journal-title":"PLoS One"},{"issue":"1\u20134 Pt. 2","key":"10.1016\/bs.irn.2018.08.002_bb0280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000099859","article-title":"Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients","volume":"69","author":"Levivier","year":"1997","journal-title":"Stereotactic and Functional Neurosurgery"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0285","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: Temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"Journal of Neurochemistry"},{"issue":"4942","key":"10.1016\/bs.irn.2018.08.002_bb0290","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1126\/science.2105529","article-title":"Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease","volume":"247","author":"Lindvall","year":"1990","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0295","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ana.410310206","article-title":"Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants","volume":"31","author":"Lindvall","year":"1992","journal-title":"Annals of Neurology"},{"issue":"20","key":"10.1016\/bs.irn.2018.08.002_bb0300","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.0b013e318292a31d","article-title":"Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD","volume":"80","author":"Loane","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0305","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.10359","article-title":"Dyskinesia after fetal cell transplantation for parkinsonism: A PET study","volume":"52","author":"Ma","year":"2002","journal-title":"Annals of Neurology"},{"issue":"Pt. 9","key":"10.1016\/bs.irn.2018.08.002_bb0310","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0315","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson disease and psychosis","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0320","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.143.6.756","article-title":"Clinical and biochemical features of depression in Parkinson's disease","volume":"143","author":"Mayeux","year":"1986","journal-title":"The American Journal of Psychiatry"},{"issue":"9138","key":"10.1016\/bs.irn.2018.08.002_bb0325","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(98)04329-3","article-title":"Positron emission tomographic evidence of toxic effect of MDMA (\u201cecstasy\u201d) on brain serotonin neurons in human beings","volume":"352","author":"McCann","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0330","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model","volume":"219","author":"Munoz","year":"2009","journal-title":"Experimental Neurology"},{"issue":"Pt. 12","key":"10.1016\/bs.irn.2018.08.002_bb0335","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiology of Disease"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0345","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/WNL.0000000000004201","article-title":"Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits","volume":"89","author":"Niccolini","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0350","doi-asserted-by":"crossref","DOI":"10.1177\/0271678X18770107","article-title":"Cerebral serotonin transporter measurements with [(11)C]DASB: A review on acquisition and preprocessing across 21 PET centres","author":"Norgaard","year":"2018","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0355","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.22208","article-title":"Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis","volume":"24","author":"Olanow","year":"2009","journal-title":"Movement Disorders"},{"issue":"15","key":"10.1016\/bs.irn.2018.08.002_bb0360","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/bs.irn.2018.08.002_bb0365","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1212\/WNL.0000000000003396","article-title":"Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease","volume":"87","author":"Pagano","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0370","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.24859","article-title":"Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies","volume":"81","author":"Pagano","year":"2017","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0375","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7861\/clinmedicine.16-4-371","article-title":"Imaging in Parkinson's disease","volume":"16","author":"Pagano","year":"2016","journal-title":"Clinical Medicine (London, England)"},{"key":"10.1016\/bs.irn.2018.08.002_bb0380","article-title":"The serotonergic system in Parkinson's patients with dyskinesia: Evidence from imaging studies","author":"Pagano","year":"2017","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0385","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/mds.26967","article-title":"Urinary dysfunction in early de novo patients with Parkinson's disease","volume":"32","author":"Pagano","year":"2017","journal-title":"Movement Disorders"},{"issue":"19","key":"10.1016\/bs.irn.2018.08.002_bb0390","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0395","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.parkreldis.2014.11.015","article-title":"Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease","volume":"21","author":"Pagano","year":"2015","journal-title":"Parkinsonism & Related Disorders"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.002_bb0400","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11910-017-0794-2","article-title":"PET molecular imaging research of levodopa-induced dyskinesias in Parkinson's disease","volume":"17","author":"Pagano","year":"2017","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0405","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/ene.13503","article-title":"Constipation is not associated with dopamine transporter pathology in early drug-naive patients with Parkinson's disease","volume":"25","author":"Pagano","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0410","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson's disease: Clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0415","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/1531-8249(199911)46:5<732::AID-ANA8>3.0.CO;2-Q","article-title":"Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias","volume":"46","author":"Papa","year":"1999","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0420","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","article-title":"The neuropathologic basis of different clinical subgroups of Parkinson's disease","volume":"50","author":"Paulus","year":"1991","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0425","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.002_bb0430","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain"},{"issue":"Pt. 3","key":"10.1016\/bs.irn.2018.08.002_bb0435","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/117.3.487","article-title":"Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon","volume":"117","author":"Peschanski","year":"1994","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2018.08.002_bb0440","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-8-80","article-title":"Dyskinesias after neural transplantation in Parkinson's disease: What do we know and what is next?","volume":"8","author":"Politis","year":"2010","journal-title":"BMC Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0445","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(17)30082-0","article-title":"Disease progression in LRRK2 parkinsonism","volume":"16","author":"Politis","year":"2017","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0450","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nbd.2011.05.009","article-title":"Serotonergic mediated body mass index changes in Parkinson's disease","volume":"43","author":"Politis","year":"2011","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2018.08.002_bb0455","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","article-title":"Serotonin in Parkinson's disease","volume":"277","author":"Politis","year":"2015","journal-title":"Behavioural Brain Research"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.002_bb0460","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","article-title":"Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin\/dopamine transporter ratio","volume":"26","author":"Politis","year":"2011","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2018.08.002_bb0465","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/bs.irn.2017.02.015","article-title":"Imaging in Parkinson's disease","volume":"132","author":"Politis","year":"2017","journal-title":"International Review of Neurobiology"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0470","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0475","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson's disease: An in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiology of Disease"},{"issue":"38","key":"10.1016\/bs.irn.2018.08.002_bb0480","doi-asserted-by":"crossref","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","article-title":"Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants","volume":"2","author":"Politis","year":"2010","journal-title":"Science Translational Medicine"},{"issue":"21","key":"10.1016\/bs.irn.2018.08.002_bb0485","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","article-title":"Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures","volume":"75","author":"Politis","year":"2010","journal-title":"Neurology"},{"issue":"Pt. 10","key":"10.1016\/bs.irn.2018.08.002_bb0490","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/brain\/awv215","article-title":"Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease","volume":"138","author":"Qamhawi","year":"2015","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2018.08.002_bb0495","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.002_bb0500","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","article-title":"Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias","volume":"86","author":"Roussakis","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.002_bb0505","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1007\/s00259-016-3349-x","article-title":"Cholinergic imaging in dementia spectrum disorders","volume":"43","author":"Roy","year":"2016","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0510","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0006-3223(98)00092-4","article-title":"Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder","volume":"44","author":"Rush","year":"1998","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0515","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0520","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/(SICI)1098-2396(199806)29:2<183::AID-SYN9>3.0.CO;2-3","article-title":"In vivo detection of short- and long-term MDMA neurotoxicity\u2014A positron emission tomography study in the living baboon brain","volume":"29","author":"Scheffel","year":"1998","journal-title":"Synapse"},{"issue":"Pt. 9","key":"10.1016\/bs.irn.2018.08.002_bb0525","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/brain\/aww190","article-title":"Serotonergic loss underlying apathy in Parkinson's disease","volume":"139","author":"Schrag","year":"2016","journal-title":"Brain"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0530","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/brain\/awy072","article-title":"Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease","volume":"141","author":"Schulz","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0535","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mds.26369","article-title":"Striatal and cortical beta-amyloidopathy and cognition in Parkinson's disease","volume":"31","author":"Shah","year":"2016","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0540","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000161058","article-title":"Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia","volume":"26","author":"Sharp","year":"2008","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.08.002_bb0545","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2011.02.026","article-title":"5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment","volume":"61","author":"Shen","year":"2011","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0550","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.neurobiolaging.2014.12.037","article-title":"The role of pallidal serotonergic function in Parkinson's disease dyskinesias: A positron emission tomography study","volume":"36","author":"Smith","year":"2015","journal-title":"Neurobiology of Aging"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0555","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mds.24061","article-title":"Apathy in Parkinson's disease: Diagnostic and etiological dilemmas","volume":"27","author":"Starkstein","year":"2012","journal-title":"Movement Disorders"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.002_bb0560","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0024-3205(93)90440-E","article-title":"[11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET","volume":"53","author":"Suehiro","year":"1993","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0565","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/syn.890200107","article-title":"Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652","volume":"20","author":"Szabo","year":"1995","journal-title":"Synapse"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0570","first-page":"678","article-title":"Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions","volume":"43","author":"Szabo","year":"2002","journal-title":"Journal of Nuclear Medicine"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0575","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00004647-199909000-00004","article-title":"Kinetic analysis of [11C]McN5652: A serotonin transporter radioligand","volume":"19","author":"Szabo","year":"1999","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0580","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mds.26456","article-title":"Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient parkinsonism","volume":"31","author":"Taylor","year":"2016","journal-title":"Movement Disorders"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.002_bb0585","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/mds.20837","article-title":"Predictors of weight loss in Parkinson's disease","volume":"21","author":"Uc","year":"2006","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0590","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/jcbfm.2010.55","article-title":"Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain","volume":"31","author":"Varnas","year":"2011","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.002_bb0595","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.neurobiolaging.2013.08.025","article-title":"Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease","volume":"35","author":"Varrone","year":"2014","journal-title":"Neurobiology of Aging"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.002_bb0600","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/syn.21823","article-title":"5-HT1B receptor imaging and cognition: A positron emission tomography study in control subjects and Parkinson's disease patients","volume":"69","author":"Varrone","year":"2015","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.002_bb0605","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000119395","article-title":"Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease","volume":"35","author":"Volpi","year":"1997","journal-title":"Neuropsychobiology"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0610","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/mds.20555","article-title":"Antidepressant studies in Parkinson's disease: A review and meta-analysis","volume":"20","author":"Weintraub","year":"2005","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.002_bb0615","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/ene.13002","article-title":"Depression, anxiety, and apathy in Parkinson's disease: Insights from neuroimaging studies","volume":"23","author":"Wen","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"22","key":"10.1016\/bs.irn.2018.08.002_bb0620","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJM199211263272203","article-title":"Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"327","author":"Widner","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.002_bb0625","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1474-4422(17)30056-X","article-title":"Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: Cross-sectional studies","volume":"16","author":"Wile","year":"2017","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2018.08.002_bb0630","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","article-title":"Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: A retrospective autopsy study","volume":"4","author":"Williams","year":"2005","journal-title":"Lancet Neurology"},{"issue":"16","key":"10.1016\/bs.irn.2018.08.002_bb0635","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1021\/jm000079i","article-title":"Novel radiotracers for imaging the serotonin transporter by positron emission tomography: Synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines","volume":"43","author":"Wilson","year":"2000","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2018.08.002_bb0640","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","article-title":"Serotonergic dysregulation is linked to sleep problems in Parkinson's disease","volume":"18","author":"Wilson","year":"2018","journal-title":"NeuroImage. Clinical"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.002_bb0645","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0024-3205(00)01021-3","article-title":"Carbon-11 labelled cholecystokininB antagonists: Radiosynthesis and evaluation in rats","volume":"68","author":"Wilson","year":"2001","journal-title":"Life Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.002_bb0650","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00415-009-0118-9","article-title":"Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study","volume":"256","author":"Wolz","year":"2009","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0655","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4613-0381-7_4","article-title":"Brain serotonin, carbohydrate-craving, obesity and depression","volume":"398","author":"Wurtman","year":"1996","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.002_bb0660","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ijnp\/pyx051","article-title":"Fenfluramine reduces [11C]Cimbi-36 binding to the 5-HT2A receptor in the nonhuman primate brain","volume":"20","author":"Yang","year":"2017","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2018.08.002_bb0665","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jns.2018.02.032","article-title":"Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease","volume":"387","author":"Yousaf","year":"2018","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2018.08.002_bb0670","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.sleep.2017.11.1137","article-title":"Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness","volume":"43","author":"Yousaf","year":"2018","journal-title":"Sleep Medicine"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.002_bb0675","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: A review","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs & Aging"},{"issue":"22","key":"10.1016\/bs.irn.2018.08.002_bb0680","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006698","article-title":"Efficacy of antidepressive medication for depression in Parkinson disease: A network meta-analysis","volume":"96","author":"Zhuo","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.002_bb0685","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/med.20245","article-title":"5-HT radioligands for human brain imaging with PET and SPECT","volume":"33","author":"Paterson","year":"2013","journal-title":"Medicinal Research Reviews"}],"container-title":["International Review of Neurobiology","Imaging in Movement Disorders: Imaging Methodology and Applications in Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774218300679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774218300679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T21:04:31Z","timestamp":1661979871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774218300679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128154182"],"references-count":137,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2018.08.002","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}